{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:50:17Z","timestamp":1794322217215,"version":"4.9.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC TR 128 B07"],"award-info":[{"award-number":["CRC TR 128 B07"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC TR128 A 08"],"award-info":[{"award-number":["CRC TR128 A 08"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR332 B02"],"award-info":[{"award-number":["TRR332 B02"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC TR128 A09, A10, Z02"],"award-info":[{"award-number":["CRC TR128 A09, A10, Z02"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RFA180-2202-39141"],"award-info":[{"award-number":["RFA180-2202-39141"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RFA-2203-39281"],"award-info":[{"award-number":["RFA-2203-39281"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RFA180-2202-39141"],"award-info":[{"award-number":["RFA180-2202-39141"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Current multiple sclerosis (MS) treatments reduce relapse activity but have limited impact on disease progression. Clinical trials targeting progression often fail because of insufficient understanding of its underlying mechanisms. This study analyzed a clinically well-characterized MS autopsy cohort from the Netherland Brain Bank (186 individuals) from which we selected donors exhibiting opposite disease trajectories of slow versus rapid progression. We performed extensive unbiased histology and spatial transcriptomics, which unveiled a distinct MS lesion type marked by an extensive myeloid cell rim with cellular and transcriptional signatures of innate immune activation, inflammatory cytokine production, unfolded protein response and apoptosis. Presence of this particular lesion type was linked to rapid disease progression. An independent translocator protein 18-kDa positron emission tomography study (114 individuals) validates the association between lesions with a broad myeloid cell rim and disease progression in individuals with MS. Our findings offer crucial insights into the mechanisms behind MS progression, identifying broad rim lesions as a biomarker for rapid disease progression and potentially guiding patient selection for future therapeutic trials targeting central nervous system intrinsic inflammation.<\/jats:p>","DOI":"10.1038\/s41591-025-03625-7","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T05:04:48Z","timestamp":1745903088000},"page":"2016-2026","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-9633","authenticated-orcid":false,"given":"Luisa","family":"Klotz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9766-8661","authenticated-orcid":false,"given":"Joost","family":"Smolders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2589-2549","authenticated-orcid":false,"given":"Jussi","family":"Lehto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5597-2670","authenticated-orcid":false,"given":"Markus","family":"Matilainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"L\u00fctje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzia","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7206-3719","authenticated-orcid":false,"given":"Julian","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4310-3432","authenticated-orcid":false,"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6695-5684","authenticated-orcid":false,"given":"Marjo","family":"Nylund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6642-7774","authenticated-orcid":false,"given":"Christian","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gardberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8886-8928","authenticated-orcid":false,"given":"Aletta M. R.","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9751-5881","authenticated-orcid":false,"given":"Laura","family":"Airas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Huitinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0174-5042","authenticated-orcid":false,"given":"Tanja","family":"Kuhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"3625_CR1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/B978-0-12-819410-2.00024-2","volume":"184","author":"M Stampanoni Bassi","year":"2022","unstructured":"Stampanoni Bassi, M., Iezzi, E. & Centonze, D. Multiple sclerosis: inflammation, autoimmunity and plasticity. Handb. Clin. Neurol. 184, 457\u2013470 (2022).","journal-title":"Handb. Clin. Neurol."},{"key":"3625_CR2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278\u2013286 (2014).","journal-title":"Neurology"},{"key":"3625_CR3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","volume":"80","author":"C Tur","year":"2023","unstructured":"Tur, C. et al. Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol. 80, 151\u2013160 (2023).","journal-title":"JAMA Neurol."},{"key":"3625_CR4","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos, L. et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 77, 1132\u20131140 (2020).","journal-title":"JAMA Neurol."},{"key":"3625_CR5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"BAC Cree","year":"2019","unstructured":"Cree, B. A. C. et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann. Neurol. 85, 653\u2013666 (2019).","journal-title":"Ann. Neurol."},{"key":"3625_CR6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","volume":"18","author":"D Ontaneda","year":"2019","unstructured":"Ontaneda, D., Tallantyre, E., Kalincik, T., Planchon, S. M. & Evangelou, N. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol. 18, 973\u2013980 (2019).","journal-title":"Lancet Neurol."},{"key":"3625_CR7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He, A. et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 19, 307\u2013316 (2020).","journal-title":"Lancet Neurol."},{"key":"3625_CR8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann, T. et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 22, 78\u201388 (2023).","journal-title":"Lancet Neurol."},{"key":"3625_CR9","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1177\/1352458517690618","volume":"23","author":"A Manouchehrinia","year":"2017","unstructured":"Manouchehrinia, A. et al. Age Related Multiple Sclerosis Severity Score: disability ranked by age. Mult. Scler. 23, 1938\u20131946 (2017).","journal-title":"Mult. Scler."},{"key":"3625_CR10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-016-1653-y","volume":"133","author":"T Kuhlmann","year":"2017","unstructured":"Kuhlmann, T. et al. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 133, 13\u201324 (2017).","journal-title":"Acta Neuropathol."},{"key":"3625_CR11","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181a8260a","volume":"72","author":"T Goldschmidt","year":"2009","unstructured":"Goldschmidt, T., Antel, J., K\u00f6nig, F. B., Br\u00fcck, W. & Kuhlmann, T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 72, 1914\u20131921 (2009).","journal-title":"Neurology"},{"key":"3625_CR12","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/jnc.16089","volume":"168","author":"W Firth","year":"2024","unstructured":"Firth, W. et al. Regulation of astrocyte metabolism by mitochondrial translocator protein 18\u2009kDa. J. Neurochem. 168, 1374\u20131401 (2024).","journal-title":"J. Neurochem."},{"key":"3625_CR13","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/glia.24052","volume":"69","author":"E Nutma","year":"2021","unstructured":"Nutma, E. et al. Activated microglia do not increase 18\u2009kDa translocator protein (TSPO) expression in the multiple sclerosis brain. Glia 69, 2447\u20132458 (2021).","journal-title":"Glia"},{"key":"3625_CR14","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1177\/13524585221114750","volume":"28","author":"AI Altokhis","year":"2022","unstructured":"Altokhis, A. I. et al. Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis. Mult. Scler. 28, 2202\u20132211 (2022).","journal-title":"Mult. Scler."},{"key":"3625_CR15","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000206614","volume":"102","author":"R Galbusera","year":"2024","unstructured":"Galbusera, R. et al. Characteristics, prevalence, and clinical relevance of juxtacortical paramagnetic rims in patients with multiple sclerosis. Neurology 102, e207966 (2024).","journal-title":"Neurology"},{"key":"3625_CR16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","volume":"476","author":"S Sawcer","year":"2011","unstructured":"Sawcer, S. et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214\u2013219 (2011).","journal-title":"Nature"},{"key":"3625_CR17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41586-023-06250-x","volume":"619","author":"A Harroud","year":"2023","unstructured":"Harroud, A. et al. Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature 619, 323\u2013331 (2023).","journal-title":"Nature"},{"key":"3625_CR18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fnins.2015.00264","volume":"9","author":"S Stone","year":"2015","unstructured":"Stone, S. & Lin, W. The unfolded protein response in multiple sclerosis. Front. Neurosci. 9, 264 (2015).","journal-title":"Front. Neurosci."},{"key":"3625_CR19","doi-asserted-by":"crossref","first-page":"682633","DOI":"10.3389\/fnagi.2021.682633","volume":"13","author":"D Fern\u00e1ndez","year":"2021","unstructured":"Fern\u00e1ndez, D., Geisse, A., Bernales, J. I., Lira, A. & Osorio, F. The unfolded protein response in immune cells as an emerging regulator of neuroinflammation. Front. Aging Neurosci. 13, 682633 (2021).","journal-title":"Front. Aging Neurosci."},{"key":"3625_CR20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41586-021-03892-7","volume":"597","author":"M Absinta","year":"2021","unstructured":"Absinta, M. et al. A lymphocyte\u2013microglia\u2013astrocyte axis in chronic active multiple sclerosis. Nature 597, 709\u2013714 (2021).","journal-title":"Nature"},{"key":"3625_CR21","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell 169, 1276\u20131290 (2017).","journal-title":"Cell"},{"key":"3625_CR22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41586-019-1404-z","volume":"573","author":"L Schirmer","year":"2019","unstructured":"Schirmer, L. et al. Neuronal vulnerability and multilineage diversity in multiple sclerosis. Nature 573, 75\u201382 (2019).","journal-title":"Nature"},{"key":"3625_CR23","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/s41593-019-0532-y","volume":"22","author":"R Sankowski","year":"2019","unstructured":"Sankowski, R. et al. Mapping microglia states in the human brain through the integration of high-dimensional techniques. Nat. Neurosci. 22, 2098\u20132110 (2019).","journal-title":"Nat. Neurosci."},{"key":"3625_CR24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00401-018-1818-y","volume":"135","author":"S Luchetti","year":"2018","unstructured":"Luchetti, S. et al. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis. Acta Neuropathol. 135, 511\u2013528 (2018).","journal-title":"Acta Neuropathol."},{"key":"3625_CR25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","volume":"15","author":"D Rotstein","year":"2019","unstructured":"Rotstein, D. & Montalban, X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat. Rev. Neurol. 15, 287\u2013300 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"3625_CR26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1474-4422(18)30460-5","volume":"18","author":"O Ciccarelli","year":"2019","unstructured":"Ciccarelli, O. et al. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurol. 18, 185\u2013197 (2019).","journal-title":"Lancet Neurol."},{"key":"3625_CR27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrneurol.2015.80","volume":"11","author":"H Kearney","year":"2015","unstructured":"Kearney, H., Miller, D. H. & Ciccarelli, O. Spinal cord MRI in multiple sclerosis\u2014diagnostic, prognostic and clinical value. Nat. Rev. Neurol. 11, 327\u2013338 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"3625_CR28","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/brain\/awy352","volume":"142","author":"D Eden","year":"2019","unstructured":"Eden, D. et al. Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. Brain 142, 633\u2013646 (2019).","journal-title":"Brain"},{"key":"3625_CR29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2309439","volume":"390","author":"P Vermersch","year":"2024","unstructured":"Vermersch, P. et al. Inhibition of CD40L with frexalimab in multiple sclerosis. N. Engl. J. Med. 390, 589\u2013600 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3625_CR30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41583-018-0093-1","volume":"20","author":"J Yuan","year":"2019","unstructured":"Yuan, J., Amin, P. & Ofengeim, D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat. Rev. Neurosci. 20, 19\u201333 (2019).","journal-title":"Nat. Rev. Neurosci."},{"key":"3625_CR31","doi-asserted-by":"crossref","first-page":"101417","DOI":"10.1016\/j.arr.2021.101417","volume":"70","author":"MS Uddin","year":"2021","unstructured":"Uddin, M. S., Yu, W. S. & Lim, L. W. Exploring ER stress response in cellular aging and neuroinflammation in Alzheimer\u2019s disease. Ageing Res. Rev. 70, 101417 (2021).","journal-title":"Ageing Res. Rev."},{"key":"3625_CR32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ana.25197","volume":"83","author":"R Magliozzi","year":"2018","unstructured":"Magliozzi, R. et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann. Neurol. 83, 739\u2013755 (2018).","journal-title":"Ann. Neurol."},{"key":"3625_CR33","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.523","volume":"5","author":"Y Estornes","year":"2014","unstructured":"Estornes, Y. et al. RIPK1 promotes death receptor-independent caspase-8-mediated apoptosis under unresolved ER stress conditions. Cell Death Dis. 5, e1555 (2014).","journal-title":"Cell Death Dis."},{"key":"3625_CR34","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1007\/s12035-024-03981-4","volume":"61","author":"Y Xu","year":"2024","unstructured":"Xu, Y. et al. Ripks and neuroinflammation. Mol. Neurobiol. 61, 6771\u20136787 (2024).","journal-title":"Mol. Neurobiol."},{"key":"3625_CR35","doi-asserted-by":"crossref","first-page":"14050","DOI":"10.1074\/jbc.M117.799304","volume":"292","author":"JA Willy","year":"2017","unstructured":"Willy, J. A. et al. Function of inhibitor of Bruton\u2019s tyrosine kinase isoform \u03b1 (IBTK\u03b1) in nonalcoholic steatohepatitis links autophagy and the unfolded protein response. J. Biol. Chem. 292, 14050\u201314065 (2017).","journal-title":"J. Biol. Chem."},{"key":"3625_CR36","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1136\/annrheumdis-2013-204143","volume":"74","author":"LM Hartkamp","year":"2015","unstructured":"Hartkamp, L. M. et al. Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. Ann. Rheum. Dis. 74, 1603\u20131611 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"3625_CR37","doi-asserted-by":"crossref","first-page":"668131","DOI":"10.3389\/fcell.2021.668131","volume":"9","author":"SFH Neys","year":"2021","unstructured":"Neys, S. F. H., Hendriks, R. W. & Corneth, O. B. J. Targeting Bruton\u2019s tyrosine kinase in inflammatory and autoimmune pathologies. Front. Cell Dev. Biol. 9, 668131 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"3625_CR38","doi-asserted-by":"crossref","unstructured":"ECTRIMS 2024 \u2013 Late breaking oral presentations. Oral presentations 0135 and 0136. Mult. Scler. J. 30, 1138\u20131147 (2024).","DOI":"10.1177\/13524585241269216"},{"key":"3625_CR39","unstructured":"Phase 2 trial on potential new drug for MS pulled. MS-UK https:\/\/ms-uk.org\/news\/phase-2-trial-on-potential-new-drug-for-ms-pulled\/#:~:text=Pharmaceutical%20company%20Sanofi%20has%20decided,not%20meet%20its%20intended%20goals (2024)."},{"key":"3625_CR40","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3389\/fimmu.2017.01810","volume":"8","author":"DAE Hendrickx","year":"2017","unstructured":"Hendrickx, D. A. E. et al. Gene expression profiling of multiple sclerosis pathology identifies early patterns of demyelination surrounding chronic active lesions. Front. Immunol. 8, 1810 (2017).","journal-title":"Front. Immunol."},{"key":"3625_CR41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s40478-019-0855-7","volume":"7","author":"ML Elkjaer","year":"2019","unstructured":"Elkjaer, M. L. et al. Molecular signature of different lesion types in the brain white matter of patients with progressive multiple sclerosis. Acta Neuropathol. Commun. 7, 205 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"3625_CR42","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/brain\/awaa158","volume":"143","author":"K J\u00e4ckle","year":"2020","unstructured":"J\u00e4ckle, K. et al. Molecular signature of slowly expanding lesions in progressive multiple sclerosis. Brain 143, 2073\u20132088 (2020).","journal-title":"Brain"},{"key":"3625_CR43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41586-019-0903-2","volume":"566","author":"S J\u00e4kel","year":"2019","unstructured":"J\u00e4kel, S. et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature 566, 543\u2013547 (2019).","journal-title":"Nature"},{"key":"3625_CR44","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00401-022-02497-2","volume":"144","author":"T Trobisch","year":"2022","unstructured":"Trobisch, T. et al. Cross-regional homeostatic and reactive glial signatures in multiple sclerosis. Acta Neuropathol. 144, 987\u20131003 (2022).","journal-title":"Acta Neuropathol."},{"key":"3625_CR45","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41586-019-0924-x","volume":"566","author":"T Masuda","year":"2019","unstructured":"Masuda, T. et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 566, 388\u2013392 (2019).","journal-title":"Nature"},{"key":"3625_CR46","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1038\/s41593-024-01765-6","volume":"27","author":"AM Alsema","year":"2024","unstructured":"Alsema, A. M. et al. Spatially resolved gene signatures of white matter lesion progression in multiple sclerosis. Nat. Neurosci. 27, 2341\u20132353 (2024).","journal-title":"Nat. Neurosci."},{"key":"3625_CR47","doi-asserted-by":"crossref","first-page":"e200133","DOI":"10.1212\/NXI.0000000000200133","volume":"10","author":"E Polvinen","year":"2023","unstructured":"Polvinen, E., Matilainen, M., Nylund, M., Sucksdorff, M. & Airas, L. M. TSPO-detectable chronic active lesions predict disease progression in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 10, e200133 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"3625_CR48","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamaneurol.2019.2399","volume":"76","author":"M Absinta","year":"2019","unstructured":"Absinta, M. et al. Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol. 76, 1474\u20131483 (2019).","journal-title":"JAMA Neurol."},{"key":"3625_CR49","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab134","volume":"3","author":"CA Treaba","year":"2021","unstructured":"Treaba, C. A. et al. Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression. Brain Commun. 3, fcab134 (2021).","journal-title":"Brain Commun."},{"key":"3625_CR50","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/13524585231162262","volume":"29","author":"C Elliott","year":"2023","unstructured":"Elliott, C. et al. Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis. Mult. Scler. 29, 680\u2013690 (2023).","journal-title":"Mult. Scler."},{"key":"3625_CR51","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/13524585221141964","volume":"29","author":"A Calvi","year":"2023","unstructured":"Calvi, A. et al. Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis. Mult. Scler. 29, 352\u2013362 (2023).","journal-title":"Mult. Scler."},{"key":"3625_CR52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s00401-024-02742-w","volume":"147","author":"A de Boer","year":"2024","unstructured":"de Boer, A. et al. Disentangling the heterogeneity of multiple sclerosis through identification of independent neuropathological dimensions. Acta Neuropathol. 147, 90 (2024).","journal-title":"Acta Neuropathol."},{"key":"3625_CR53","volume":"12","author":"A Eshaghi","year":"2021","unstructured":"Eshaghi, A. et al. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nat. Commun. 12, 2078 (2021).","journal-title":"Nat. Commun."},{"key":"3625_CR54","doi-asserted-by":"crossref","first-page":"eade8560","DOI":"10.1126\/scitranslmed.ade8560","volume":"16","author":"CC Gross","year":"2024","unstructured":"Gross, C. C. et al. Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories. Sci. Transl. Med. 16, eade8560 (2024).","journal-title":"Sci. Transl. Med."},{"key":"3625_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1679\/aohc.70.1","volume":"70","author":"R Meguro","year":"2007","unstructured":"Meguro, R. et al. Nonheme-iron histochemistry for light and electron microscopy: a historical, theoretical and technical review. Arch. Histol. Cytol. 70, 1\u201319 (2007).","journal-title":"Arch. Histol. Cytol."},{"key":"3625_CR56","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1093\/nar\/gkad1026","volume":"52","author":"N Liu","year":"2024","unstructured":"Liu, N. et al. standR: spatial transcriptomic analysis for GeoMx DSP data. Nucleic Acids Res. 52, e2 (2024).","journal-title":"Nucleic Acids Res."},{"key":"3625_CR57","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"3625_CR58","unstructured":"Chen, H. VennDiagram: Generate high-resolution Venn and Euler plots. R package version 1.7.3 https:\/\/cran.r-project.org\/web\/packages\/VennDiagram\/index.html (2022)."},{"key":"3625_CR59","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/ene.15834","volume":"30","author":"J Lehto","year":"2023","unstructured":"Lehto, J. et al. Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis. Eur. J. Neurol. 30, 2365\u20132375 (2023).","journal-title":"Eur. J. Neurol."},{"key":"3625_CR60","doi-asserted-by":"crossref","first-page":"fcab301","DOI":"10.1093\/braincomms\/fcab301","volume":"4","author":"M Nylund","year":"2022","unstructured":"Nylund, M. et al. Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18\u2009kDa translocator protein-PET. Brain Commun. 4, fcab301 (2022).","journal-title":"Brain Commun."},{"key":"3625_CR61","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1212\/NXI.0000000000000574","volume":"6","author":"M Sucksdorff","year":"2019","unstructured":"Sucksdorff, M. et al. Natalizumab treatment reduces microglial activation in the white matter of the MS brain. Neurol. Neuroimmunol. Neuroinflamm. 6, e574 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"3625_CR62","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mrm.20426","volume":"53","author":"LC Chang","year":"2005","unstructured":"Chang, L. C., Jones, D. K. & Pierpaoli, C. RESTORE: robust estimation of tensors by outlier rejection. Magn. Reson. Med. 53, 1088\u20131095 (2005).","journal-title":"Magn. Reson. Med."},{"key":"3625_CR63","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan, J. et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 16, 834\u2013840 (1996).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"3625_CR64","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1093\/brain\/awv258","volume":"138","author":"T Kalincik","year":"2015","unstructured":"Kalincik, T. et al. Defining reliable disability outcomes in multiple sclerosis. Brain 138, 3287\u20133298 (2015).","journal-title":"Brain"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03625-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03625-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03625-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:10:30Z","timestamp":1776899430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03625-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3625"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03625-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.K. receives research support from the DFG, the Interdisciplinary Center for Clinical Research (IZKF) M\u00fcnster, the National MS Society, Biogen, Novartis and Merck Serono. She received compensation for serving on scientific advisory boards and speaker honoraria from Alexion, Amgen, Argenx, Bayer, Biogen, Bristol Myers Squibb, Grifols, Hexal, Horizon, Janssen, Merck Serono, Novartis, Roche, Sandoz, Sanofi, Santhera, Teva and Viatris. J.S. receives research support from Roche, Siemens Healthineers, Hansa Biopharma, Stichting MS research, Stichting klimmen tegen MS (MOVES inspiration grant), Nationaal MS fonds and the Erasmus Foundation, and received speaker honoraria or consultancy fees from Biogen, Merck, Novartis, Roche and Sanofi. He serves on the steering committee of the International Progressive MS Alliance, the scientific advisory board of Stichting MS research and several committees of the Dutch Society for Neurology. J.L. received speaker honoraria from Merck and Sanofi. H.W. receives research support from the DFG, the Deutsche Myasthenie Gesellschaft, the European Union, Alexion, Amicus Therapeutics, Argenx, Biogen, CSL Behring, F. Hoffmann-La Roche, Genzyme, Merck KGaA, Novartis, Roche and UCB Biopharma, as well as speaker honoraria or consultancy fees from Alexion, Argenx, Argobio, AOCN, AstraZeneca, BGP Products Operations, Biogen, Bristol Myers Squibb, CEMCAT, Dianthus, EMD Serono, EPG Health\/Medthority, Fondazione Cariplo, Genzyme, Idorsia, Immunic, Immunovant, INmune Bio Syneos Health, Kohlhammer, LTS, Lundbeck, Merck, MS at the Limits, Muna Therapeutics, Myrobalan Therapeutics, Neurodiem, NMSS, Novartis, Ology, PSL Group, Red Nucleus, Roche, Samsung, Sangamo, Sanofi, Springer, StreamedUp, the Swiss MS Society, Teladochealth, Toleranzia, Teva, UCB, Uvet, Viatris and WebMD global. He is a member of the scientific advisory boards of Alexion, Argenx, Biocryst, Bristol Myers Squibb, Cellerys, Galapagos, Janssen, Merck, Novartis, Sandoz-Hexal and uniQure biopharma. L.A. receives grants from the Research Council of Finland, the Aatos Erkko Foundation, the US National MS Society, Merck Serono and Sanofi. She has received speaker and advisory honoraria from Sanofi, Biogen, Novartis, Kiniksa, Continuum Therapeutics and Merck. I.H. has received compensation for serving on the scientific advisory board of Muna Therapeutics and serves on a speakers\u2019 panel for Novartis. T.K. receives research funding from the DFG, IZKF M\u00fcnster, the National MS Society, the German MS Society and Novartis. She has received compensation for serving on the scientific advisory boards of Novartis, Sanofi and Merck, and speaker honoraria from Novartis, Biogen, Sanofi and Roche. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}